JJET is a pioneering company in the field of cardiac electrophysiology, specializing in the development and commercialization of advanced medical devices for the diagnosis and treatment of heart rhythm disorders. The company serves healthcare providers, hospitals, and clinics, primarily in the Chinese market but with a growing international presence. JJET's product portfolio includes electrophysiology catheters, ablation catheters, and a 3D cardiac mapping system, all designed to improve the precision and effectiveness of cardiac procedures. The business model is based on the sale of these high-tech medical devices, as well as strategic collaborations with global leaders in the cardiac EP field. Revenue is generated through direct sales, partnerships, and acquisitions, such as the successful acquisition of CARDIMA INC. in 2011. JJET's innovative solutions have received multiple regulatory approvals, including NMPA and China Food and Drug Administration certifications, ensuring compliance with stringent medical standards. The company's commitment to research and development is evident in its continuous product advancements and strategic collaborations, positioning it as a leader in the cardiac electrophysiology market.

Keywords: cardiac electrophysiology, 3D mapping, ablation catheters, healthcare providers, medical devices, heart rhythm disorders, regulatory approvals, strategic collaborations, international market, research and development.